Aplagon

Pioneering first-in-class treatments for thromboinflammatory diseases

Helsinki, Finland · Founded 2009 · $9.9M raised

Headquarters
Helsinki
Founded
2009
Business Model
B2B
Total Funding
$9.9M
Last Round
$7.3M Venture RoundFeb 2025
Rounds
2

About

Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for thromboinflammatory diseases. It is based on pioneering research on mast cell-derived heparin proteoglycans (HEP-PG) by Prof. Riitta Lassila's group at the Wihuri Research Institute in Helsinki, Finland, which led to Aplagon's lead candidate APAC — a heparin proteoglycan mimetic now in clinical studies across two lead cardiovascular indications. Aplagon's offices and laboratory are at Biomedicum Helsinki, a prominent life-science hub in Finland.

Summary

Aplagon is a Biotech company based in Helsinki, Finland, founded in 2009. It has raised $9.9M in total across 2 rounds, most recently a $7.3M Venture Round round in Feb 2025. Investors include Fåhraeus Startup and Growth, European Innovation Council Fund and Innovestor.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture RoundFeb 2025
$7.3M

Sign up to see all 2 rounds

Venture Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Aplagon on Indexed.vc
<a href="https://indexed.vc/companies/aplagon"><img src="https://indexed.vc/api/badge/company/aplagon" alt="Aplagon on Indexed.vc" width="260" height="76" /></a>